Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Higher Plasma Methylglyoxal Levels are Associated with Incident Cardiovascular Disease in Individuals with Type 1 Diabetes: a 12-Year Follow-Up Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Liraglutide preserved insulin secretion in adults with newly diagnosed type 1 diabetes: the NewLira trial

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. Long-acting neurotensin synergizes with liraglutide to reverse obesity through a Melanocortin-dependent pathway

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Nordin M J Hanssen
  • Jean L J M Scheijen
  • Anders Jorsal
  • Hans-Henrik Parving
  • Lise Tarnow
  • Peter Rossing
  • Coen D A Stehouwer
  • Casper G Schalkwijk
Vis graf over relationer

Methylglyoxal (MGO), a major precursor for advanced glycation endproducts (AGEs), is increased in diabetes. In diabetic rodents, inhibition of MGO prevents cardiovascular disease (CVD). Whether plasma MGO levels are associated with incident CVD in people with type 1 diabetes is unknown. We included 159 individuals with persistent normoalbuminuria and 162 individuals with diabetic nephropathy (DN) from the outpatient clinic at Steno Diabetes Center. We measured MGO at baseline. We recorded fatal and non-fatal CVD over a median follow-up of 12.3 years (interquartile range 7.6-12.5). Data were analyzed with Cox regression, with adjustment for sex, age, HbA1c, DN, diabetes duration, smoking, systolic blood pressure, anti-hypertensive medication and BMI. During follow-up, 73 individuals suffered at least one CVD event (36 fatal and 53 non-fatal events). Higher MGO levels were associated with total, fatal and nonfatal incident CVD (HRs: 1.47; 95%CI: 1.13-1.91, 1.42; 95%CI: 1.01-1.99 and 1.46; 95%CI: 1.08-1.98, respectively). We observed a similar trend for total mortality (HR: 1.24; 95%CI: 0.99-1.56). This study shows, for the first time, that plasma MGO levels are associated with cardiovascular events in individuals with type 1 diabetes. MGO may explain the increased risk, at least in part, for CVD in type 1 diabetes.

Udgave nummer8
Sider (fra-til)2278-83
StatusUdgivet - 2017

ID: 50608096